Carteolol

Research use only, not for human use.

A non-selective beta blocker used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.

A non-selective beta blocker used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.Other Indication Approved.

Carteolol (0-2%; 0-28 hours; HCECs) has cytotoxicity and decreases cell viability in a dose- and time-dependent manner.Carteolol (0.25%; 4-12 hours; HCECs) induces apoptosis and necroptotic protein expression in HCECs. Cell Viability Assay Cell Line:HCECs Concentration:0.00390625-2%Incubation Time:0, 2, 4, 8, 16, 20,24 and 28 hoursResult:Decreased cell viability with the concentrations above 0.0015625% in a dose- and time-dependent manner.Western Blot Analysis Cell Line:HCECs Concentration:0.25% Incubation Time:4, 8 and 12 hours Result:Dampened expression of the anti-apoptotic protein Bcl-2 and Bcl-xL, enhanced expression of the pro-apoptotic proteins Bax and Bad, and mitochondrial-released pro-apoptotic proteins Cyt.c and AIF.Cell Cycle Analysis Cell Line:HCECs Concentration:0.25% Incubation Time:4, 8 and 12 hours Result:Increased the number of G1 phase of the cell cycle, whereas decreased S phase.

——

——

GPCR/G Protein

Adrenergic Receptor

Adrenergic Receptor

Other Indications

Other Disease

51781-06-7

292.373

C16H24N2O3

>98% (HPLC)

——

CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O

5-[3-[(1,1-Dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-2(1H)-quinolinone

(-20℃)

With Ice Pack

≥ 2 years